"ASSOCIATION_TYPE"	"PMID"	"NUM_SENTENCE"	"ENTITY1_TEXT"	"ENTITY1_INI"	"ENTITY1_END"	"ENTITY1_TYPE"	"ENTITY2_TEXT"	"ENTITY2_INI"	"ENTITY2_END"	"ENTITY2_TYPE"	"SENTENCE"
"PA"	17938326	0	"ABCG2"	71	76	"Genes & Molecular Sequences"	"doxorubicin"	43	54	"Chemicals & Drugs"	"Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines."
"PA"	17938326	5	"EGFR"	16	20	"Genes & Molecular Sequences"	"gefitinib"	31	40	"Chemicals & Drugs"	"Inactivation of EGFR kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence."
"PA"	17938326	0	"ABCG2"	71	76	"Genes & Molecular Sequences"	"Gefitinib"	0	9	"Chemicals & Drugs"	"Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines."
"PA"	17938326	2	"ABCG2 drug transporter"	161	183	"Genes & Molecular Sequences"	"doxorubicin"	140	151	"Chemicals & Drugs"	"Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib."
"PA"	17938326	12	"EGFR"	20	24	"Genes & Molecular Sequences"	"gefitinib"	35	44	"Chemicals & Drugs"	"Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin."
"PA"	17938326	8	"ABCG2 drug transporter"	80	102	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17938326	6	"ABCG2"	128	133	"Genes & Molecular Sequences"	"doxorubicin"	172	183	"Chemicals & Drugs"	"A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of doxorubicin."
"PA"	17938326	9	"ABCG2"	126	131	"Genes & Molecular Sequences"	"doxorubicin"	93	104	"Chemicals & Drugs"	"Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA."
"PA"	17938326	12	"EGFR"	20	24	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin."
"PA"	17938326	8	"EGFR"	14	18	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17938326	8	"ABCG2 drug transporter"	80	102	"Genes & Molecular Sequences"	"gefitinib"	38	47	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"SA"	17938326	13	"ABCG2"	18	23	"Genes & Molecular Sequences"	"doxorubicin"	67	78	"Chemicals & Drugs"	"The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer."
"PA"	17938326	8	"EGFR"	14	18	"Genes & Molecular Sequences"	"gefitinib"	38	47	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17395790	3	"oxytocin"	151	159	"Genes & Molecular Sequences"	"GSK221149A"	0	10	"Chemicals & Drugs"	"GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18."
"PA"	17395790	5	"oxytocin"	72	80	"Genes & Molecular Sequences"	"GSK221149A"	23	33	"Chemicals & Drugs"	"Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing."
"PA"	17395790	4	"oxytocin"	79	87	"Genes & Molecular Sequences"	"GSK221149A"	30	40	"Chemicals & Drugs"	"Intravenous administration of GSK221149A produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml)."
"PA"	18445086	2	"PML/RARalpha"	0	12	"Genes & Molecular Sequences"	"ATRA"	62	66	"Chemicals & Drugs"	"PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies."
"PA"	18445086	7	"PML/RARalpha"	63	75	"Genes & Molecular Sequences"	"ATRA"	0	4	"Chemicals & Drugs"	"ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors."
"PA"	18426370	1	"K65R mutation"	139	152	"SNP & Sequence variations"	"tenofovir"	302	311	"Chemicals & Drugs"	"Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use."
"PA"	18610736	6	"ATP7B"	34	39	"Genes & Molecular Sequences"	"copper ions"	78	89	"Chemicals & Drugs"	"One among the 17 genes studied is ATP7B which is involved in the transport of copper ions across the cell membrane into the cell."
"FA"	17875725	0	"Topoisomerase IIbeta"	0	20	"Genes & Molecular Sequences"	"dexrazoxane"	117	128	"Chemicals & Drugs"	"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane."
"FA"	17875725	0	"Topoisomerase IIbeta"	0	20	"Genes & Molecular Sequences"	"doxorubicin"	72	83	"Chemicals & Drugs"	"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane."
"PA"	17875725	7	"Top2beta"	120	128	"Genes & Molecular Sequences"	"doxorubicin"	164	175	"Chemicals & Drugs"	"Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"MG132"	107	112	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"PA"	17875725	6	"Top2beta"	286	294	"Genes & Molecular Sequences"	"Doxorubicin"	0	11	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"Doxorubicin"	0	11	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"PA"	17875725	8	"Top2beta"	152	160	"Genes & Molecular Sequences"	"dexrazoxane"	35	46	"Chemicals & Drugs"	"Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity."
"PA"	17875725	7	"Top2beta"	120	128	"Genes & Molecular Sequences"	"dexrazoxane"	74	85	"Chemicals & Drugs"	"Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage."
"SA"	17875725	8	"Top2beta"	152	160	"Genes & Molecular Sequences"	"doxorubicin"	164	175	"Chemicals & Drugs"	"Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity."
"PA"	17875725	9	"Top2beta"	43	51	"Genes & Molecular Sequences"	"doxorubicin"	148	159	"Chemicals & Drugs"	"The specific involvement of proteasome and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks."
"PA"	17875725	6	"Top2beta"	286	294	"Genes & Molecular Sequences"	"bortezomib"	92	102	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"bortezomib"	92	102	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	19056662	3	"PMCA1b"	214	220	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	3	"TRPV6"	152	157	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"SA"	19056662	10	"TRPV6"	66	71	"Genes & Molecular Sequences"	"FOS"	176	179	"Chemicals & Drugs"	"We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats."
"PA"	19056662	4	"calbindin-D9k"	47	60	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"FA"	19056662	4	"PMCA1b"	80	86	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"PA"	19056662	4	"TRPV6"	37	42	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"FA"	19056662	3	"plasma membrane calcium-ATPase 1b"	179	212	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	3	"calbindin-D9k"	160	173	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	9	"TRPV6"	246	251	"Genes & Molecular Sequences"	"FOS"	192	195	"Chemicals & Drugs"	"These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6."
"FA"	17402796	1	"tumor necrosis factor"	108	129	"Genes & Molecular Sequences"	"Adalimumab"	0	10	"Chemicals & Drugs"	"Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)."
"PA"	17402796	1	"TNF"	131	134	"Genes & Molecular Sequences"	"Adalimumab"	0	10	"Chemicals & Drugs"	"Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)."
"PA"	18602931	0	"P2X7 receptors"	136	150	"Genes & Molecular Sequences"	"[3H]A-804598"	0	12	"Chemicals & Drugs"	"[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors."
"PA"	18602931	4	"P2X7 receptors"	238	252	"Genes & Molecular Sequences"	"A-804598"	56	64	"Chemicals & Drugs"	"While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors."
"FA"	18602931	9	"P2X antagonists"	32	47	"Genes & Molecular Sequences"	"[3H]A-804598"	59	71	"Chemicals & Drugs"	"The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05)."
"FA"	18602931	9	"P2X7 receptors"	144	158	"Genes & Molecular Sequences"	"[3H]A-804598"	59	71	"Chemicals & Drugs"	"The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05)."
"FA"	18602931	5	"P2X7 receptors"	148	162	"Genes & Molecular Sequences"	"A-804598"	0	8	"Chemicals & Drugs"	"A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors."
"PA"	18602931	5	"IL-1beta"	61	69	"Genes & Molecular Sequences"	"A-804598"	0	8	"Chemicals & Drugs"	"A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors."
"PA"	18602931	10	"P2X7 receptors"	224	238	"Genes & Molecular Sequences"	"A-804598"	28	36	"Chemicals & Drugs"	"These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors."
"PA"	17293381	7	"CYP3A"	40	45	"Genes & Molecular Sequences"	"MA"	0	2	"Chemicals & Drugs"	"MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively."
"FA"	17293381	5	"CYP3A"	22	27	"Genes & Molecular Sequences"	"MD"	0	2	"Chemicals & Drugs"	"MD did not inactivate CYP3A."
"PA"	17293381	0	"CYP3A"	82	87	"Genes & Molecular Sequences"	"diltiazem"	41	50	"Chemicals & Drugs"	"Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A."
"PA"	17293381	2	"CYP3A"	99	104	"Genes & Molecular Sequences"	"diltiazem"	74	83	"Chemicals & Drugs"	"We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted CYP3A inactivation in hepatocytes."
"PA"	17293381	6	"CYP3A"	114	119	"Genes & Molecular Sequences"	"diltiazem"	215	224	"Chemicals & Drugs"	"Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent."
"PA"	17293381	6	"CYP3A"	114	119	"Genes & Molecular Sequences"	"MA"	263	265	"Chemicals & Drugs"	"Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent."
"PA"	17293381	10	"CYP3A"	114	119	"Genes & Molecular Sequences"	"MA"	49	51	"Chemicals & Drugs"	"In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem."
"PA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MD"	133	135	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"diltiazem"	185	194	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	4	"CYP3A"	78	83	"Genes & Molecular Sequences"	"diltiazem"	170	179	"Chemicals & Drugs"	"In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml."
"FA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MA"	146	148	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	4	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MA"	27	29	"Chemicals & Drugs"	"In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml."
"PA"	17293381	7	"CYP3A"	40	45	"Genes & Molecular Sequences"	"MD"	7	9	"Chemicals & Drugs"	"MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively."
"FA"	18591256	9	"Bcr-Abl"	3	10	"Genes & Molecular Sequences"	"Gleevec"	106	113	"Chemicals & Drugs"	"In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance."
"PA"	18591256	9	"Hsp90beta"	65	74	"Genes & Molecular Sequences"	"Gleevec"	106	113	"Chemicals & Drugs"	"In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance."
"FA"	17626206	8	"TRPV1 channels"	70	84	"Genes & Molecular Sequences"	"AMG0347"	159	166	"Chemicals & Drugs"	"We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests."
"PA"	17626206	4	"TRPV1"	192	197	"Genes & Molecular Sequences"	"AMG0347"	181	188	"Chemicals & Drugs"	"We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent."
"PA"	17626206	6	"TRPV1"	214	219	"Genes & Molecular Sequences"	"AMG0347"	154	161	"Chemicals & Drugs"	"The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors."
"PA"	17276892	0	"p38"	157	160	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	0	"ERK"	162	165	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	0	"nuclear factor-kappaB"	170	191	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	6	"ICAM-1"	169	175	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"SA"	17276892	6	"p38"	86	89	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"PA"	17276892	0	"intercellular adhesion molecule-1"	19	52	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"SA"	17276892	6	"NF-kappaB"	99	108	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"FA"	17276892	6	"TNF-alpha"	151	160	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"PA"	17276892	3	"p65"	117	120	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"IkappaBalpha"	210	222	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"inhibitory factor kappaBalpha"	179	208	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"FA"	17276892	0	"tumor necrosis factor-alpha"	67	94	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	5	"TNF-alpha"	210	219	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha."
"SA"	17276892	2	"ICAM-1"	64	70	"Genes & Molecular Sequences"	"paeonol"	158	165	"Chemicals & Drugs"	"We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs)."
"PA"	17276892	3	"ICAM-1"	62	68	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"nuclear factor-kappaB"	83	104	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"NF-kappaB"	106	115	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"SA"	17276892	6	"ERK"	91	94	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"FA"	17967141	3	"HDL3"	154	158	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	0	"LDL"	131	134	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	0	"Scavenger receptor of class B"	0	29	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	3	"scavenger receptors"	47	66	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	0	"HDL3"	139	143	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	3	"LDL"	146	149	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	13	"HDL3"	143	147	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"FA"	17967141	13	"LDL"	135	138	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"FA"	17967141	12	"LDL"	30	33	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	12	"HDL3"	38	42	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	12	"SR-B receptors"	110	124	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	13	"SR-B receptors"	151	165	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"PA"	18026124	3	"CB1"	108	111	"Genes & Molecular Sequences"	"endocannabinoids"	17	33	"Chemicals & Drugs"	"On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms."
"FA"	18026124	3	"CB2"	112	115	"Genes & Molecular Sequences"	"endocannabinoids"	17	33	"Chemicals & Drugs"	"On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms."
"PA"	18026124	5	"CB1"	85	88	"Genes & Molecular Sequences"	"synthetic CB1 receptor agonists"	23	54	"Chemicals & Drugs"	"Previous studies using synthetic CB1 receptor agonists or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models."
"FA"	18026124	8	"CB receptors"	65	77	"Genes & Molecular Sequences"	"CB2 receptor agonists"	262	283	"Chemicals & Drugs"	"This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage."
"PA"	18026124	7	"CB2"	123	126	"Genes & Molecular Sequences"	"CB2 receptor agonists"	41	62	"Chemicals & Drugs"	"Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage."
"FA"	17620431	2	"VEGF"	237	241	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF) receptors"	94	109	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"c-Kit tyrosine kinases"	164	186	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"platelet-derived growth factor receptor"	119	158	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"VEGFR"	111	116	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF"	237	241	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"VEGFR"	111	116	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"platelet-derived growth factor receptor"	119	158	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"c-Kit tyrosine kinases"	164	186	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF) receptors"	94	109	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17701832	5	"CYP3A4"	82	88	"Genes & Molecular Sequences"	"5HT3 antagonists"	34	50	"Chemicals & Drugs"	"The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity."
"FA"	17701832	5	"CYP1A2"	116	122	"Genes & Molecular Sequences"	"5HT3 antagonists"	34	50	"Chemicals & Drugs"	"The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity."
"FA"	18573490	0	"interleukin-1beta"	138	155	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"FA"	18573490	4	"IkappaB) kinase beta"	200	220	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"FA"	18573490	4	"IKKbeta"	222	229	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"PA"	18573490	0	"inhibitory kappaB"	88	105	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"PA"	18573490	6	"IKKbeta"	152	159	"Genes & Molecular Sequences"	"LYR-71"	13	19	"Chemicals & Drugs"	"Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity."
"PA"	18573490	6	"IL-1beta"	169	177	"Genes & Molecular Sequences"	"LYR-71"	13	19	"Chemicals & Drugs"	"Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity."
"FA"	18573490	4	"NF-kappaB"	258	267	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"PA"	18573490	5	"NF-kappaB"	223	232	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"PA"	18573490	7	"NF-kappaB"	73	82	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"PA"	18573490	7	"IKKbeta"	53	60	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"PA"	18573490	5	"IKKbeta"	17	24	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"PA"	18573490	5	"IkappaBalpha"	157	169	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"SA"	18573490	7	"inflammatory cytokines"	212	234	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"FA"	18573490	0	"nuclear factor-kappaB"	45	66	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"PA"	17502872	2	"TNF"	93	96	"Genes & Molecular Sequences"	"infliximab"	220	230	"Chemicals & Drugs"	"To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab)."
"PA"	19024103	8	"JNK"	83	86	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"P38"	91	94	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"EGFR"	19	23	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"ERK1"	77	81	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	18544460	6	"VEGF"	92	96	"Genes & Molecular Sequences"	"bevacizumab"	62	73	"Chemicals & Drugs"	"Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer."
"PA"	18544460	6	"EGFR"	52	56	"Genes & Molecular Sequences"	"cetuximab"	27	36	"Chemicals & Drugs"	"Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer."
"PA"	17511782	4	"EGFR"	151	155	"Genes & Molecular Sequences"	"5-fluorouracil"	101	115	"Chemicals & Drugs"	"Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity."
"PA"	17599377	8	"CYP1A1"	80	86	"Genes & Molecular Sequences"	"TCDD"	90	94	"Chemicals & Drugs"	"In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by TCDD was significantly decreased."
"PA"	17599377	2	"CYP1A1"	66	72	"Genes & Molecular Sequences"	"TCDD"	52	56	"Chemicals & Drugs"	"Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression."
"PA"	17599377	9	"CYP1A1"	105	111	"Genes & Molecular Sequences"	"TCDD"	32	36	"Chemicals & Drugs"	"Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia."
"PA"	17599377	9	"CYP1A1"	105	111	"Genes & Molecular Sequences"	"cycloheximide"	74	87	"Chemicals & Drugs"	"Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia."
"PA"	17599377	2	"CYP1A1"	66	72	"Genes & Molecular Sequences"	"2,3,7,8-tetrachlorodibenzo-p-dioxin"	15	50	"Chemicals & Drugs"	"Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression."
"PA"	17599377	3	"AhR"	55	58	"Genes & Molecular Sequences"	"TCDD"	81	85	"Chemicals & Drugs"	"In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by TCDD was significantly inhibited."
"PA"	17345086	3	"P-gp"	82	86	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"PA"	17345086	3	"MRP1"	93	97	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"PA"	17345086	2	"BCRP"	49	53	"Genes & Molecular Sequences"	"flavonoids"	33	43	"Chemicals & Drugs"	"We previously reported that some flavonoids have BCRP-inhibitory activity."
"FA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"mitoxantrone"	159	171	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"PA"	17345086	0	"breast cancer resistance protein"	19	51	"Genes & Molecular Sequences"	"Flavonoids"	0	10	"Chemicals & Drugs"	"Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship."
"PA"	17345086	3	"BCRP"	75	79	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"FA"	17345086	4	"BCRP"	104	108	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"NA"	17345086	12	"MRP1"	48	52	"Genes & Molecular Sequences"	"flavonoids"	12	22	"Chemicals & Drugs"	"None of the flavonoids that we tested inhibited MRP1."
"PA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"3',4',7-trimethoxyflavone"	30	55	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"FA"	17345086	11	"P-gp"	158	162	"Genes & Molecular Sequences"	"acacetin"	51	59	"Chemicals & Drugs"	"Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp."
"PA"	17345086	7	"BCRP"	16	20	"Genes & Molecular Sequences"	"topotecan"	88	97	"Chemicals & Drugs"	"The reversal of BCRP activity was tested by measuring the fluorescence of intracellular topotecan."
"FA"	17345086	11	"P-gp"	158	162	"Genes & Molecular Sequences"	"3',4',7-trimethoxyflavone"	21	46	"Chemicals & Drugs"	"Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp."
"PA"	17345086	13	"BCRP"	75	79	"Genes & Molecular Sequences"	"flavonoids"	44	54	"Chemicals & Drugs"	"Our present results thus indicate that many flavonoids selectively inhibit BCRP only."
"FA"	17345086	4	"P-gp"	43	47	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"FA"	17345086	4	"MRP1"	53	57	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"FA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"SN-38"	135	140	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"PA"	18337476	2	"NPSR"	367	371	"Genes & Molecular Sequences"	"SHA 66"	78	84	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	2	"NPS receptor"	353	365	"Genes & Molecular Sequences"	"SHA 68"	174	180	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	7	"NPS"	95	98	"Genes & Molecular Sequences"	"SHA 68"	42	48	"Chemicals & Drugs"	"Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior."
"PA"	18337476	0	"neuropeptide S receptor"	194	217	"Genes & Molecular Sequences"	"SHA 68"	155	161	"Chemicals & Drugs"	"Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor."
"PA"	18337476	2	"NPS receptor"	353	365	"Genes & Molecular Sequences"	"SHA 66"	78	84	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	2	"NPSR"	367	371	"Genes & Molecular Sequences"	"SHA 68"	174	180	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	3	"NPSR"	92	96	"Genes & Molecular Sequences"	"SHA 68"	55	61	"Chemicals & Drugs"	"The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to NPSR in the nanomolar range."
"PA"	18337476	8	"NPS"	119	122	"Genes & Molecular Sequences"	"SHA 68"	11	17	"Chemicals & Drugs"	"Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo."
"PA"	18927209	5	"mTOR"	100	104	"Genes & Molecular Sequences"	"P2281"	85	90	"Chemicals & Drugs"	"In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"P2281"	557	562	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"FA"	18927209	6	"TNF-alpha"	135	144	"Genes & Molecular Sequences"	"P2281"	203	208	"Chemicals & Drugs"	"In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function."
"PA"	18927209	6	"IFN-gamma"	106	115	"Genes & Molecular Sequences"	"P2281"	203	208	"Chemicals & Drugs"	"In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"DSS"	570	573	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"dextran sulfate sodium"	7	29	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"PA"	17167170	4	"caspase-3"	261	270	"Genes & Molecular Sequences"	"GW501516"	51	59	"Chemicals & Drugs"	"In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition."
"PA"	17167170	4	"caspase-3"	261	270	"Genes & Molecular Sequences"	"L-165041"	39	47	"Chemicals & Drugs"	"In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition."
"FA"	18341639	0	"FLT3 internal tandem duplication"	136	168	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"PA"	18341639	5	"FLT3/WT"	61	68	"SNP & Sequence variations"	"lestaurtinib"	45	57	"Chemicals & Drugs"	"FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004)."
"FA"	18341639	2	"FLT3/TKD+"	134	143	"SNP & Sequence variations"	"FLT3 inhibitors"	72	87	"Chemicals & Drugs"	"Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level."
"FA"	18341639	0	"tyrosine kinase domain mutation of FLT3"	43	82	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"NA"	18341639	4	"FLT3/TKD"	182	190	"SNP & Sequence variations"	"cytarabine"	139	149	"Chemicals & Drugs"	"All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact."
"FA"	18341639	0	"FLT3 internal tandem duplication"	136	168	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"FA"	18341639	8	"FLT3/TKD+"	27	36	"SNP & Sequence variations"	"FLT3 inhibitors"	129	144	"Chemicals & Drugs"	"These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors."
"FA"	18341639	6	"FLT3/TKD+"	99	108	"SNP & Sequence variations"	"lestaurtinib"	50	62	"Chemicals & Drugs"	"There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells."
"PA"	18341639	5	"FLT3/TKD+"	0	9	"SNP & Sequence variations"	"lestaurtinib"	45	57	"Chemicals & Drugs"	"FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004)."
"FA"	18341639	8	"FLT3/WT"	41	48	"SNP & Sequence variations"	"FLT3 inhibitors"	129	144	"Chemicals & Drugs"	"These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors."
"PA"	18341639	4	"FLT3/ITD"	87	95	"SNP & Sequence variations"	"cytarabine"	139	149	"Chemicals & Drugs"	"All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact."
"PA"	18676772	9	"telomerase"	89	99	"Genes & Molecular Sequences"	"GRN163L"	65	72	"Chemicals & Drugs"	"The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis."
"PA"	17805244	2	"PPARgamma"	230	239	"Genes & Molecular Sequences"	"NSAID"	192	197	"Chemicals & Drugs"	"The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma."
"PA"	17805244	2	"PPARgamma"	230	239	"Genes & Molecular Sequences"	"NSAIDs"	14	20	"Chemicals & Drugs"	"The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma."
"FA"	17893038	0	"RAGE"	25	29	"Genes & Molecular Sequences"	"statins"	80	87	"Chemicals & Drugs"	"Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"imatinib"	24	32	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"SA"	18202009	3	"CXCR4"	79	84	"Genes & Molecular Sequences"	"INNO-406"	57	65	"Chemicals & Drugs"	"We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells."
"PA"	18202009	5	"CXCR4"	17	22	"Genes & Molecular Sequences"	"imatinib"	115	123	"Chemicals & Drugs"	"This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha."
"PA"	18202009	0	"CXCR4"	0	5	"Genes & Molecular Sequences"	"imatinib"	23	31	"Chemicals & Drugs"	"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells."
"FA"	18202009	5	"CXCR4"	17	22	"Genes & Molecular Sequences"	"IFN-alpha"	127	136	"Chemicals & Drugs"	"This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"INNO-406"	34	42	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"PA"	18202009	9	"CXCR4"	61	66	"Genes & Molecular Sequences"	"imatinib"	70	78	"Chemicals & Drugs"	"Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"IFN-alpha"	47	56	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"SA"	18202009	3	"CXCR4"	79	84	"Genes & Molecular Sequences"	"imatinib"	45	53	"Chemicals & Drugs"	"We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells."
"PA"	18348297	13	"adiponectin"	106	117	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"PA"	18348297	13	"HDL cholesterol"	85	100	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"NA"	18348297	13	"C-reactive protein"	179	197	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"PA"	18497344	5	"insulin-like growth factor binding protein 5"	63	107	"Genes & Molecular Sequences"	"progesterone"	41	53	"Chemicals & Drugs"	"Also upregulated were genes inhibited by progesterone, such as insulin-like growth factor binding protein 5."
"PA"	18524848	6	"GLI"	32	35	"Genes & Molecular Sequences"	"doxorubicin"	270	281	"Chemicals & Drugs"	"Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin."
"PA"	18155663	6	"SOD"	92	95	"Genes & Molecular Sequences"	"RZG"	0	3	"Chemicals & Drugs"	"RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression."
"NA"	18155663	2	"PDX-1"	93	98	"Genes & Molecular Sequences"	"RZG"	21	24	"Chemicals & Drugs"	"We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation."
"NA"	18155663	2	"insulin"	102	109	"Genes & Molecular Sequences"	"RZG"	21	24	"Chemicals & Drugs"	"We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation."
"PA"	18155663	6	"GPx"	84	87	"Genes & Molecular Sequences"	"RZG"	0	3	"Chemicals & Drugs"	"RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression."
"PA"	17535976	7	"PPARgamma"	184	193	"Genes & Molecular Sequences"	"bisphenol A diglycidyl ether"	58	86	"Chemicals & Drugs"	"The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions."
"PA"	19047160	6	"p53/56 Lyn"	27	37	"Genes & Molecular Sequences"	"nilotinib"	194	203	"Chemicals & Drugs"	"Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"nilotinib"	15	24	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"SA"	19047160	0	"Pgp"	61	64	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"SA"	19047160	0	"Src kinase"	69	79	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"PA"	19047160	9	"p53/56 Lyn"	182	192	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"PP1"	27	30	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"PP2"	35	38	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"PSC833"	117	123	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"PA"	19047160	6	"Lyn"	131	134	"Genes & Molecular Sequences"	"nilotinib"	194	203	"Chemicals & Drugs"	"Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib."
"PA"	19047160	9	"Lyn"	115	118	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"verapamil"	104	113	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"PA"	19047160	10	"Lyn"	126	129	"Genes & Molecular Sequences"	"imatinib"	61	69	"Chemicals & Drugs"	"Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance."
"PA"	19047160	7	"Lyn mRNA"	75	83	"Genes & Molecular Sequences"	"nilotinib"	21	30	"Chemicals & Drugs"	"Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML."
"PA"	19047160	9	"Bcr-Abl"	149	156	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"Src kinase inhibitors"	4	25	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"PA"	19047160	10	"Lyn"	126	129	"Genes & Molecular Sequences"	"nilotinib"	133	142	"Chemicals & Drugs"	"Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance."
"SA"	19047160	0	"BCR-ABL"	52	59	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"FA"	18234154	0	"ABCC1"	85	90	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	0	"ABCB1"	30	35	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	0	"P-glycoprotein"	14	28	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"PA"	18234154	7	"Pgp"	143	146	"Genes & Molecular Sequences"	"CBT-1"	114	119	"Chemicals & Drugs"	"CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated ATP hydrolysis."
"NA"	18234154	9	"ABCG2"	56	61	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport."
"PA"	18234154	6	"Pgp"	43	46	"Genes & Molecular Sequences"	"paclitaxel"	83	93	"Chemicals & Drugs"	"Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells."
"PA"	18234154	8	"MRP1"	78	82	"Genes & Molecular Sequences"	"CBT-1"	40	45	"Chemicals & Drugs"	"In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated calcein transport."
"PA"	18234154	11	"Pgp"	131	134	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"FA"	18234154	11	"ABC transporters"	29	45	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"FA"	18234154	0	"multidrug resistance-associated protein"	42	81	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	3	"Pgp"	78	81	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor."
"PA"	18234154	6	"Pgp"	43	46	"Genes & Molecular Sequences"	"vinblastine"	70	81	"Chemicals & Drugs"	"Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells."
"PA"	18234154	11	"MRP1"	142	146	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"PA"	17304149	1	"P-glycoprotein"	68	82	"Genes & Molecular Sequences"	"paroxetine"	39	49	"Chemicals & Drugs"	"A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein."
"SA"	17304149	9	"P-glycoprotein"	138	152	"Genes & Molecular Sequences"	"paroxetine"	180	190	"Chemicals & Drugs"	"The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine."
"FA"	17304149	2	"P-glycoprotein"	72	86	"Genes & Molecular Sequences"	"paroxetine"	114	124	"Chemicals & Drugs"	"However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of paroxetine."
"PA"	18165569	10	"CYP2D6"	55	61	"Genes & Molecular Sequences"	"epidural infusion of ropivacaine"	13	45	"Chemicals & Drugs"	"A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation."
"PA"	18165569	1	"CYP2D6"	66	72	"Genes & Molecular Sequences"	"Ropivacaine"	0	11	"Chemicals & Drugs"	"Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in."
"PA"	18165569	6	"CYP2D6"	51	57	"Genes & Molecular Sequences"	"debrisoquine"	24	36	"Chemicals & Drugs"	"Patients received 10 mg debrisoquine (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion."
"PA"	18165569	1	"CYP2D6"	66	72	"Genes & Molecular Sequences"	"pipecoloxylidide"	40	56	"Chemicals & Drugs"	"Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in."
"PA"	18165569	10	"CYP2D6"	55	61	"Genes & Molecular Sequences"	"debrisoquine"	160	172	"Chemicals & Drugs"	"A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation."
